GRK 6 Inhibitors
The chemical class of GRK6 inhibitors encompasses a diverse array of compounds that intricately regulate the activity of G protein-coupled receptor kinase 6 (GRK6), a crucial regulator of GPCR signaling. These inhibitors, employing both direct and indirect mechanisms, offer insights into the multifaceted control of GRK6 function and its integration into broader cellular processes. Direct inhibitors, such as Paroxetine, SB 218078, Gallein, and Propranolol, exert their effects by directly targeting GRK6's kinase activity or disrupting its interaction with key cellular components. Paroxetine, a selective serotonin reuptake inhibitor, interferes with serotonin signaling, leading to direct inhibition of GRK6. SB 218078 directly targets GRK6's catalytic domain, inhibiting its phosphorylation of GPCRs. Gallein disrupts the interaction between GRK6 and G protein subunits, preventing its recruitment to activated GPCRs. Propranolol, a non-selective beta-adrenergic receptor antagonist, competes with beta-adrenergic receptors, blocking the activation of GRK6.
Indirect inhibitors, such as Compstatin, Heptanol, and U0126, modulate GRK6 activity by influencing complement activation, lipid raft dynamics, or the MAPK pathway, respectively. Compstatin indirectly inhibits GRK6 by suppressing complement activation, which can impact GPCR signaling. Heptanol disrupts lipid raft integrity, indirectly modulating GRK6 through changes in GPCR spatial organization. U0126 inhibits the MAPK pathway, affecting GRK6 activity and its role in GPCR phosphorylation. Additional indirect inhibitors, including Wortmannin, Valsartan, Dynasore, and Sunitinib, target specific cellular processes or signaling pathways to regulate GRK6. Wortmannin interferes with PI3K-dependent signaling, indirectly modulating GRK6 activity and GPCR phosphorylation. Valsartan, an ARB, indirectly inhibits GRK6 by influencing the renin-angiotensin system and its effects on GPCR signaling. Dynasore affects endocytosis, indirectly regulating GRK6 by influencing GPCR availability for phosphorylation. Sunitinib targets receptor tyrosine kinases, indirectly inhibiting GRK6 and its role in GPCR signaling.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Paroxetine | 61869-08-7 | sc-507527 | 1 g | $180.00 | ||
Paroxetine, a selective serotonin reuptake inhibitor (SSRI), directly inhibits GRK6 by modulating the serotonin signaling pathway. By blocking the reuptake of serotonin, paroxetine alters intracellular signaling cascades, leading to the inhibition of GRK6. | ||||||
SB 218078 | 135897-06-2 | sc-203692 | 1 mg | $136.00 | 1 | |
SB 218078, a cell-permeable compound, directly inhibits GRK6 by interfering with its kinase activity. This direct inhibition occurs through the specific targeting of the catalytic domain of GRK6, preventing its phosphorylation of G protein-coupled receptors (GPCRs). SB 218078 acts as a competitive inhibitor, binding to the active site of GRK6 and disrupting its ability to phosphorylate GPCRs, thus inhibiting downstream signaling events associated with GRK6 activity. | ||||||
Gallein | 2103-64-2 | sc-202631 | 50 mg | $85.00 | 20 | |
Gallein, a small molecule, directly inhibits GRK6 by disrupting its interaction with G protein βγ subunits. This direct inhibition occurs through the interference with the interaction between GRK6 and G protein subunits, preventing the recruitment of GRK6 to activated G protein-coupled receptors (GPCRs). | ||||||
1-Heptanol | 111-70-6 | sc-237561 | 100 ml | $113.00 | ||
Heptanol, an alcohol compound, indirectly inhibits GRK6 by affecting lipid raft dynamics. Lipid rafts are involved in GPCR localization and signaling, and heptanol disrupts lipid raft integrity, indirectly modulating GRK6 activity. This indirect inhibition occurs through the impact on the spatial organization of GPCRs within the membrane, influencing the accessibility of GRK6 to its substrates. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin, a phosphoinositide 3-kinase (PI3K) inhibitor, indirectly inhibits GRK6 by disrupting PI3K-dependent signaling pathways. PI3K signaling can modulate GPCR phosphorylation by GRK6, and wortmannin inhibits this process by targeting PI3K. This indirect inhibition occurs through the interference with PI3K-mediated signaling events that regulate GRK6 activity, providing insights into the crosstalk between PI3K signaling and GPCR phosphorylation by GRK6. | ||||||
Propranolol | 525-66-6 | sc-507425 | 100 mg | $180.00 | ||
Propranolol, a non-selective beta-adrenergic receptor antagonist, directly inhibits GRK6 by interfering with GPCR signaling. By blocking beta-adrenergic receptors, propranolol disrupts the activation of GRK6 and its subsequent phosphorylation of GPCRs. This direct inhibition occurs through the competitive antagonism of beta-adrenergic receptors, preventing the recruitment and activation of GRK6, thereby modulating GPCR signaling events associated with GRK6 activity. | ||||||
Valsartan | 137862-53-4 | sc-220362 sc-220362A sc-220362B | 10 mg 100 mg 1 g | $40.00 $92.00 $122.00 | 4 | |
Valsartan, an angiotensin II receptor blocker (ARB), indirectly inhibits GRK6 by modulating the renin-angiotensin system. Angiotensin II signaling can influence GRK6 activity, and valsartan blocks the angiotensin II receptor, indirectly modulating GRK6. | ||||||
Dynamin Inhibitor I, Dynasore | 304448-55-3 | sc-202592 | 10 mg | $89.00 | 44 | |
Dynasore, a dynamin inhibitor, indirectly inhibits GRK6 by affecting endocytosis. Dynamin is involved in GPCR internalization, and dynasore inhibits this process, indirectly modulating GRK6 activity. This indirect inhibition occurs through the interference with dynamin-dependent endocytosis, influencing the availability of GPCRs for GRK6 phosphorylation. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Sunitinib, a receptor tyrosine kinase inhibitor, indirectly inhibits GRK6 by affecting receptor tyrosine kinase signaling pathways. Receptor tyrosine kinases can modulate GPCR phosphorylation by GRK6, and sunitinib inhibits this process by targeting these kinases. | ||||||